Navidea Biopharma (NAVB) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Navidea Reports First Quarter 2015 Financial Results; Reiterates 2015 Lymphoseek® Revenue Guidance
May 12, 2015 7:30 AM EDTDUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), today announced financial results for the first quarter of 2015. Navidea reported total revenue for the first quarter of 2015 of $2.1 million, including Lymphoseek® (technetium Tc 99m tilmanocept) injection sales revenue of $1.84 million. The net loss attributable to common stockholders was $7.3 million.
Performance year-to-date reflects our aggressive transformation into an organization singularly focused on unlocking the value of our Manocept technology as a state-of-the-art cancer imaging agent and as a novel therapeutic platform, said Rick Gonzalez, Navidea Chief Executive Officer. We executed on our stated objectives to grow... More
